171 related articles for article (PubMed ID: 25700353)
1. ENOX2 target for the anticancer isoflavone ME-143.
Morré DJ; Korty T; Meadows C; Ades LM; Morré DM
Oncol Res; 2014; 22(1):1-12. PubMed ID: 25700353
[TBL] [Abstract][Full Text] [Related]
2. ECTO-NOX target for the anticancer isoflavene phenoxodiol.
Morré DJ; Chueh PJ; Yagiz K; Balicki A; Kim C; Morré DM
Oncol Res; 2007; 16(7):299-312. PubMed ID: 17518268
[TBL] [Abstract][Full Text] [Related]
3. Molecular cloning and characterization of a candidate human growth-related and time-keeping constitutive cell surface hydroquinone (NADH) oxidase.
Jiang Z; Gorenstein NM; Morré DM; Morré DJ
Biochemistry; 2008 Dec; 47(52):14028-38. PubMed ID: 19055324
[TBL] [Abstract][Full Text] [Related]
4. Phenoxodiol treatment alters the subsequent response of ENOX2 (tNOX) and growth of hela cells to paclitaxel and cisplatin.
Morré DJ; McClain N; Wu LY; Kelly G; Morré DM
Mol Biotechnol; 2009 May; 42(1):100-9. PubMed ID: 19156549
[TBL] [Abstract][Full Text] [Related]
5. ECTO-NOX (ENOX) proteins of the cell surface lack thioredoxin reductase activity.
Bosneaga E; Kim C; Shen B; Watanabe T; Morre DM; Morré DJ
Biofactors; 2008; 34(3):245-51. PubMed ID: 19734126
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells.
De Luca T; Morré DM; Morré DJ
J Cell Biochem; 2010 Aug; 110(6):1504-11. PubMed ID: 20518072
[TBL] [Abstract][Full Text] [Related]
7. NADH oxidase activity (NOX) and enlargement of HeLa cells oscillate with two different temperature-compensated period lengths of 22 and 24 minutes corresponding to different NOX forms.
Wang S; Pogue R; Morré DM; Morré DJ
Biochim Biophys Acta; 2001 Jun; 1539(3):192-204. PubMed ID: 11420117
[TBL] [Abstract][Full Text] [Related]
8. Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol.
Wu LY; De Luca T; Watanabe T; Morré DM; Morré DJ
Biochim Biophys Acta; 2011 Aug; 1810(8):784-9. PubMed ID: 21571040
[TBL] [Abstract][Full Text] [Related]
9. Downstream targets of altered sphingolipid metabolism in response to inhibition of ENOX2 by phenoxodiol.
De Luca T; Bosneaga E; Morré DM; Morré DJ
Biofactors; 2008; 34(3):253-60. PubMed ID: 19734127
[TBL] [Abstract][Full Text] [Related]
10. Alternative splicing as the basis for specific localization of tNOX, a unique hydroquinone (NADH) oxidase, to the cancer cell surface.
Tang X; Tian Z; Chueh PJ; Chen S; Morré DM; Morré DJ
Biochemistry; 2007 Oct; 46(43):12337-46. PubMed ID: 17924659
[TBL] [Abstract][Full Text] [Related]
11. Essential role of copper in the activity and regular periodicity of a recombinant, tumor-associated, cell surface, growth-related and time-keeping hydroquinone (NADH) oxidase with protein disulfide-thiol interchange activity (ENOX2).
Tang X; Chueh PJ; Jiang Z; Layman S; Martin B; Kim C; Morré DM; Morré DJ
J Bioenerg Biomembr; 2010 Oct; 42(5):355-60. PubMed ID: 20922471
[TBL] [Abstract][Full Text] [Related]
12. Mouse embryonic fibroblast cells from transgenic mice overexpressing tNOX exhibit an altered growth and drug response phenotype.
Yagiz K; Wu LY; Kuntz CP; James Morré D; Morré DM
J Cell Biochem; 2007 May; 101(2):295-306. PubMed ID: 17115410
[TBL] [Abstract][Full Text] [Related]
13. Antisense experiments demonstrate an exon 4 minus splice variant mRNA as the basis for expression of tNOX, a cancer-specific cell surface protein.
Tang X; Morré DJ; Morré DM
Oncol Res; 2007; 16(12):557-67. PubMed ID: 18351130
[TBL] [Abstract][Full Text] [Related]
14. Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface.
Chueh PJ; Kim C; Cho N; Morré DM; Morré DJ
Biochemistry; 2002 Mar; 41(11):3732-41. PubMed ID: 11888291
[TBL] [Abstract][Full Text] [Related]
15. The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfide-thiol interchange activity.
Morré DJ; Chueh PJ; Lawler J; Morré DM
J Bioenerg Biomembr; 1998 Oct; 30(5):477-87. PubMed ID: 9932650
[TBL] [Abstract][Full Text] [Related]
16. ENOX2 (or tNOX): a new and old molecule with cancer activity involved in tumor prevention and therapy.
Ronconi G; Lessiani G; Spinas E; Kritas SK; Caraffa Al; Saggini A; Antinolfi P; Pizzicannella J; Toniato E; Conti P
J Biol Regul Homeost Agents; 2016; 30(3):649-653. PubMed ID: 27655481
[TBL] [Abstract][Full Text] [Related]
17. Specificity of coenzyme Q inhibition of an aging-related cell surface NADH oxidase (ECTO-NOX) that generates superoxide.
Morré DM; Morré DJ
Biofactors; 2003; 18(1-4):33-43. PubMed ID: 14695918
[TBL] [Abstract][Full Text] [Related]
18. Sera from cancer patients contain two oscillating ECTO-NOX activities with different period lengths.
Wang S; Morré DM; Morré DJ
Cancer Lett; 2003 Feb; 190(2):135-41. PubMed ID: 12565167
[TBL] [Abstract][Full Text] [Related]
19. Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases.
Morré DJ; Morré DM
Free Radic Res; 2003 Aug; 37(8):795-808. PubMed ID: 14567438
[TBL] [Abstract][Full Text] [Related]
20. Cancer type-specific tNOX isoforms: A putative family of redox protein splice variants with cancer diagnostic and prognostic potential.
Morré DJ; Hostetler B; Weston N; Kim C; Morré DM
Biofactors; 2008; 34(3):201-7. PubMed ID: 19734121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
